This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My File Cabinet Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by El-Beshlawy, A. Articles by Eid, K. Search for Related Content PubMed PubMed Citation Articles by El-Beshlawy, A. Articles by Eid, K. Related Collections Blood Social Bookmarking                         What's this?

PEDIATRICS Vol. 110 No. 4 October 2002, pp. e44

ELECTRONIC ARTICLE

Study of 22 Egyptian Patients With Diamond-Blackfan Anemia, Corticosteroids, and Cyclosporin Therapy Results

Amal El-Beshlawy, MD^*, Ilham Youssry Ibrahim, MD^*, Samia Rizk, MD, Khalid Eid, MD^*

^* Hematology Clinic
^Dagger; Laboratory in the New Cairo University Children’s Hospital, Cairo, Egypt

--> Objective. Diamond-Blackfan anemia is a rare congenital hypoproliferative anemia of infancy and early childhood. Treatment with corticosteroids is commonly used, but with limited success. Trials with cyclosporin-A (CSA) are not frequently reported. Therefore, in this study we analyzed our results in the management of this rare disease by different medical treatments.

Design. The results of 22 patients diagnosed at our Hematology Center in the New Cairo University Children’s Hospital during the period 1991–2001 were retrospectively analyzed. Our patients first received prednisolone (2 mg/kg/d) for different courses according to their response. Since the year 2000, the steroid nonresponders received CSA (3–12 mg/kg/d) for 6 months unless treatment complications developed.

Results. The age at the onset of the disease ranged from 1 to 24 months (median: 2.5 months). The mean values of the hemoglobin, the reticulocyte count, and the myeloid/erythroid ratio at the onset of the disease were 4.75 ± 1.79 g/dL, 0.14 ± 0.16, and 39.4 ± 27.08, respectively. Patients received prednisolone from 0.25 to 10 years (median: 2 years). Ten patients were nonresponders (45.5%), and 5 patients (22.7%) responded to corticosteroid therapy. Two of 5 responders are off treatment with a hemoglobin level of >9 g/dL, and 3 of 5 are currently corticosteroid-dependent. Of 10 patients not responding to steroids, 8 received CSA for 6 months. Four patients (50%) responded to CSA therapy. A significant positive association was found between CSA dose and response.

Conclusion. CSA therapy should be tried in steroid-resistant Diamond-Blackfan anemia patients before blood transfusion or corticosteroid therapy complications are instituted.

Key Words: Diamond-Blackfan anemia • cyclosporin-A • corticosteroids

Abbreviations: DBA, Diamond-Blackfan anemia • CSA, cyclosporin-A

---

Received for publication Feb 19, 2002; Accepted Jun 11, 2002.

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Flygare and S. Karlsson Diamond-Blackfan anemia: erythropoiesis lost in translation Blood, April 15, 2007; 109(8): 3152 - 3154. [Abstract] [Full Text] [PDF]